pyrazines has been researched along with Ewing Sarcoma in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Chramiec, A; Halligan, SP; House, JS; Liu, Y; Rusyn, I; Sakolish, C; Vunjak-Novakovic, G | 1 |
| Gordon, DJ; Goss, KL; Koppenhafer, SL; Terry, WW | 1 |
| Beckmann, RP; Blosser, W; Cole, KA; Dowless, M; Erickson, SW; Gorlick, R; Hawkins, DS; Houghton, PJ; Iversen, PW; Kang, MH; Kolb, EA; Krytska, K; Kurmasheva, RT; Lin, AB; Lowery, CD; Maris, JM; Renschler, M; Reynolds, CP; Rubin, BP; Smith, MA; Stancato, LF; Stephens, JR; Teicher, BA; VanWye, AB | 1 |
| Ambati, SR; Chiosis, G; Kosugi, K; Lopes, EC; Meyers, PA; Mony, U; Moore, MA; Moreira, AL; Shah, SK; Taldone, T; Zehir, A | 1 |
| Amaral, AT; D'Incalci, M; De Alava, E; Di Giandomenico, S; Frapolli, R; Garofalo, C; Hassan, AB; Malaguarnera, R; Manara, MC; Mancarella, C; Ordóñez, JL; Picci, P; Scotlandi, K; Sevillano, V; Uboldi, S | 1 |
| Baloglu, E; Cao, Q; Chu, P; Doan, N; Forscher, C; Gery, S; Guo, X; Koeffler, HP; Lee, VK; Lim, HJ; Lin, DC; Marijon, H; Mayakonda, A; Pang, B; Rajalingam, R; Said, JW; Shacham, S; Sun, H; Thomas, T; Xu, L; Yang, H; Zhao, Z | 1 |
| Bouvet, M; Chishima, T; DeLong, JC; Dry, SM; Eckardt, MA; Eilber, FC; Endo, I; Federman, N; Hiroshima, Y; Hoffman, RM; Igarashi, K; James, AW; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Murakami, T; Russell, T; Singh, AS; Tanaka, K; Yanagawa, J; Zhang, Y | 1 |
| Amin, HM; Benjamin, RS; Buford, AS; Daw, NC; Fokt, I; Lamhamedi-Cherradi, SE; Lazar, AJ; Ludwig, JA; Maywald, RL; Menegaz, BA; Mikos, AG; Naing, A; Priebe, W; Ramamoorthy, V; Ratan, R; Rohren, EM; Skora, S; Subbiah, V; Vishwamitra, D; Wang, J; Wang, Y | 1 |
| Billingham, L; Dutton, P; Hassan, AB; Love, SB | 1 |
| Hanada, M; Iwamoto, Y; Matsunobu, T; Nakamura, T; Nakatani, F; Okada, T; Sakimura, R; Tanaka, K | 1 |
| Chaudhary, PM; Lu, G; Punj, V | 1 |
1 trial(s) available for pyrazines and Ewing Sarcoma
| Article | Year |
|---|---|
Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; HSP90 Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Purines; Pyrazines; Sarcoma, Ewing; Xenograft Model Antitumor Assays | 2014 |
10 other study(ies) available for pyrazines and Ewing Sarcoma
| Article | Year |
|---|---|
Tissue-Engineered Bone Tumor as a Reproducible Human in Vitro Model for Studies of Anticancer Drugs.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cisplatin; Doxorubicin; Humans; Imidazoles; Osteoblasts; Pyrazines; Sarcoma, Ewing; Tissue Engineering; Tumor Microenvironment; Vincristine | 2020 |
mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells.
Topics: Adaptor Proteins, Signal Transducing; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Phosphoproteins; Phosphorylation; Protein Biosynthesis; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Sarcoma, Ewing; Xenograft Model Antitumor Assays | 2018 |
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cells, Cultured; Checkpoint Kinase 1; Child; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Humans; Mice; Neoplasms; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Sarcoma, Ewing; Xenograft Model Antitumor Assays | 2019 |
Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
Topics: 12E7 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Caspase 7; Cell Line, Tumor; Dioxoles; DNA Damage; DNA Repair; DNA-Binding Proteins; Doxorubicin; Female; Humans; Imidazoles; Insulin-Like Growth Factor I; Mice; Mice, Nude; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Proto-Oncogene Protein c-fli-1; Pyrazines; Receptor, IGF Type 1; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin | 2015 |
CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Exportin 1 Protein; Female; Gene Knockdown Techniques; Humans; Hydrazines; Imidazoles; Immunoblotting; Immunohistochemistry; Insulin-Like Growth Factor I; Karyopherins; Mice; Mice, Nude; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; Pyrazines; Real-Time Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; RNA-Binding Protein EWS; Sarcoma, Ewing; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2016 |
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Topics: Animals; Bone Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p18; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Mice; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Piperazines; Pyrazines; Pyridines; Receptor, IGF Type 1; RNA-Binding Protein FUS; Sarcoma, Ewing; Xenograft Model Antitumor Assays | 2016 |
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
Topics: Adenosine Triphosphatases; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cation Transport Proteins; Cell Line, Tumor; Copper-Transporting ATPases; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Insulin Receptor Substrate Proteins; Male; Mice; Mice, SCID; Neoplasm Transplantation; Nucleocytoplasmic Transport Proteins; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Array Analysis; Pyrazines; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptors, Somatomedin; Sarcoma, Ewing; Sirolimus; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Up-Regulation | 2016 |
Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma.
Topics: Antineoplastic Agents; Bayes Theorem; Clinical Trials, Phase II as Topic; Data Interpretation, Statistical; Humans; Imidazoles; Models, Statistical; Patient Selection; Probability; Pyrazines; Rare Diseases; Sample Size; Sarcoma, Ewing; Treatment Outcome | 2018 |
The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Histone Deacetylases; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sarcoma, Ewing; Transplantation, Heterologous; Tumor Cells, Cultured | 2007 |
Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.
Topics: Apoptosis; Bone Neoplasms; Boronic Acids; Bortezomib; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; Humans; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Sarcoma, Ewing; TNF-Related Apoptosis-Inducing Ligand | 2008 |